Moreover, our results are indirectly supported by a clinical trial on the effect of a GLP-1 RA, exenatide, on markers of bone metabolism [26], which reported that bone markers were unaffected after 44 weeks of exenatide treatment. Here, GCG is linked to rheumatoid arthritis.